SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease

Risk flags

• ●The claims are forward-looking, centered on the potential of a novel therapy for weight loss and CNS disorders.
• ●No financial data, clinical trial results, or development timelines are provided.

Announcement summary

SciSparc Ltd. announced that NeuroThera Labs Inc., in which SciSparc holds a controlling interest of approximately 75%, has advanced its collaboration with Clearmind Medicine Inc. by publishing an international patent application under the Patent Cooperation Treaty (PCT). The patent application is for a novel combination therapy aimed at treating weight loss. This development highlights ongoing collaboration between the companies and the pursuit of new therapies for central nervous system (CNS) disorders. The announcement is significant for investors due to the controlling interest and the advancement of intellectual property.

Disagree with this article?